Neorubicin is a long-acting recombinant human granulocyte colony-stimulating factor, a drug that elevates the number of leukocytes in the peripheral blood. It promotes the progenitor cells of the granulocyte lineage in the bone marrow to proliferate, divide, mature and release into the peripheral blood, increasing the number of leukocytes in the peripheral blood, as well as improving the function of leukocyte phagocytosis in the peripheral blood. It is used clinically in patients with leukopenia due to various causes, especially in the treatment of granulocytopenia due to radiotherapy and chemotherapy. It can be used once to promote the proliferation of granulocytes in the bone marrow continuously within half a month, and usually one injection can be given subcutaneously 48 hours after the cessation of chemotherapy.